DE69535195D1 - Substituierte imide als tnf inhibitoren - Google Patents

Substituierte imide als tnf inhibitoren

Info

Publication number: DE69535195D1
Authority: DE; Germany
Prior art keywords: imids; substituted; tnf inhibitors; inhibitors; phthalimido
Prior art date: 1994-12-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE69535195T

Other languages

English (en)

Other versions

DE69535195T2 (de

Inventor

George Muller

Mary Shire

I Stirling

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Celgene Corp

Original Assignee

Celgene Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-12-30

Filing date

1995-11-20

Publication date

2006-10-05

1995-11-20 Application filed by Celgene Corp filed Critical Celgene Corp

2006-10-05 Publication of DE69535195D1 publication Critical patent/DE69535195D1/de

2007-07-12 Application granted granted Critical

2007-07-12 Publication of DE69535195T2 publication Critical patent/DE69535195T2/de

2015-11-21 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 title 1
239000002451 tumor necrosis factor inhibitor Substances 0.000 title 1
GODXRDNLVMRFSG-GFCCVEGCSA-N 2-[(2r)-1-(3,4-dimethoxyphenyl)propan-2-yl]isoindole-1,3-dione Chemical group C1=C(OC)C(OC)=CC=C1C[C@@H](C)N1C(=O)C2=CC=CC=C2C1=O GODXRDNLVMRFSG-GFCCVEGCSA-N 0.000 abstract 1
206010006895 Cachexia Diseases 0.000 abstract 1
206010014824 Endotoxic shock Diseases 0.000 abstract 1
206010040070 Septic Shock Diseases 0.000 abstract 1
108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 1
150000003949 imides Chemical class 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
230000010076 replication Effects 0.000 abstract 1
241001430294 unidentified retrovirus Species 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

DE69535195T 1994-12-30 1995-11-20 Substituierte imide als tnf inhibitoren Expired - Lifetime DE69535195T2 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US366679		1982-04-08
US08/366,679 US6429221B1 (en)	1994-12-30	1994-12-30	Substituted imides
PCT/US1995/015384 WO1996020926A1 (en)	1994-12-30	1995-11-20	Substituted imides as tnf inhibitors

Publications (2)

Publication Number	Publication Date
DE69535195D1 true DE69535195D1 (de)	2006-10-05
DE69535195T2 DE69535195T2 (de)	2007-07-12

Family

ID=23444039

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE69535195T Expired - Lifetime DE69535195T2 (de)	1994-12-30	1995-11-20	Substituierte imide als tnf inhibitoren

Country Status (20)

Country	Link
US (3)	US6429221B1 (de)
EP (1)	EP0800514B1 (de)
JP (1)	JP4118329B2 (de)
KR (2)	KR100466838B1 (de)
AT (1)	ATE337301T1 (de)
AU (1)	AU709719B2 (de)
CA (1)	CA2208671C (de)
CZ (1)	CZ203697A3 (de)
DE (1)	DE69535195T2 (de)
DK (1)	DK0800514T3 (de)
ES (1)	ES2271948T3 (de)
FI (1)	FI972709A (de)
HK (1)	HK1004674A1 (de)
HU (1)	HUT77124A (de)
NZ (1)	NZ297324A (de)
PL (1)	PL185361B1 (de)
PT (1)	PT800514E (de)
RU (1)	RU2162078C2 (de)
SK (1)	SK86897A3 (de)
WO (1)	WO1996020926A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5703098A (en) *	1994-12-30	1997-12-30	Celgene Corporation	Immunotherapeutic imides/amides
US5728844A (en) *	1995-08-29	1998-03-17	Celgene Corporation	Immunotherapeutic agents
DE69700616T2 (de) *	1996-07-02	2000-03-16	Nisshin Flour Milling Co	Imid derivate
EP0918746B1 (de)	1996-08-12	2003-04-09	Celgene Corporation	Immunotherapeutische mittel und ihre anwendung in der reduzierung der cytokininwerte
US6429212B1 (en) *	1996-08-16	2002-08-06	Ishihara Sangyo Kaisha Ltd.	Medicinal composition
EP0933360A1 (de) *	1997-12-22	1999-08-04	Pharmachemie B.V.	Synthese von Beta-lactamen
ES2138561B1 (es) *	1998-04-17	2000-07-01	Univ Madrid Complutense	Uso de los peptidos vip y pacap en el tratamiento del shock endotoxico en mamiferos.
US6667316B1 (en) *	1999-11-12	2003-12-23	Celgene Corporation	Pharmaceutically active isoindoline derivatives
US6808902B1 (en)	1999-11-12	2004-10-26	Amgen Inc.	Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US6326388B1 (en) *	1999-12-21	2001-12-04	Celgene Corporation	Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
US8030343B2 (en) *	2000-06-08	2011-10-04	Celgene Corporation	Pharmaceutically active isoindoline derivatives
US7091353B2 (en)	2000-12-27	2006-08-15	Celgene Corporation	Isoindole-imide compounds, compositions, and uses thereof
EP1389203B8 (de)	2001-02-27	2010-03-10	The Governement of the United States of America, represented by The Secretary Department of Health and Human services	Analoga von thalidomid als angiogeneseinhibitoren
CN1518447A (zh) *	2001-04-23	2004-08-04	��Ǵ�ѧר��	作为抗血管生成剂的新的苯邻二甲酰亚胺模拟物的合成和评估
ES2674888T3 (es)	2001-06-26	2018-07-04	Amgen Inc.	Anticuerpos para OPGL
US7498171B2 (en)	2002-04-12	2009-03-03	Anthrogenesis Corporation	Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US20100129363A1 (en) *	2002-05-17	2010-05-27	Zeldis Jerome B	Methods and compositions using pde4 inhibitors for the treatment and management of cancers
CA2486141A1 (en) *	2002-05-17	2003-11-27	Celgene Corporation	Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
ZA200503024B (en) *	2002-10-15	2006-11-29	Celgene Corp	Selective cytokine inhibitory drugs for treating myelodysplastic syndrome
US20040087558A1 (en) *	2002-10-24	2004-05-06	Zeldis Jerome B.	Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
US7776907B2 (en) *	2002-10-31	2010-08-17	Celgene Corporation	Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
KR100923173B1 (ko)	2002-11-06	2009-10-22	셀진 코포레이션	암 및 다른 질환의 치료 및 관리를 위한 선택적 시토킨억제 약물의 사용 방법 및 그 조성물
CA2505003A1 (en) *	2002-11-06	2004-05-27	Celgene Corporation	Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
CA2506232A1 (en) *	2002-11-18	2004-06-03	Celgene Corporation	Methods of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
AU2003294312A1 (en) *	2002-11-18	2004-07-09	Celgene Corporation	Methods of usig and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
DE60330187D1 (de) *	2002-12-30	2009-12-31	Celgene Corp	Fluoralkoxy-substituierte 1, 3-dihydro-isoindolyl-verbindungen und ihre pharmazeutischen verwendungen
US20040175382A1 (en) *	2003-03-06	2004-09-09	Schafer Peter H.	Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
JP4943845B2 (ja)	2003-09-17	2012-05-30	ザガバメントオブザユナイテッドステイツオブアメリカアズリプレゼンティッドバイザセクレタリーオブザデパートメントオブヘルスアンドヒューマンサービシーズ	サリドマイド類似体
US8952895B2 (en)	2011-06-03	2015-02-10	Apple Inc.	Motion-based device operations
US20050142104A1 (en) *	2003-11-06	2005-06-30	Zeldis Jerome B.	Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders
AU2004293443A1 (en)	2003-11-19	2005-06-09	Signal Pharmaceuticals, Llc.	Indazole Compounds and methods of use thereof as protein kinase inhibitors
US7684506B2 (en)	2004-02-13	2010-03-23	Panasonic Corporation	Transmitter apparatus, receiver apparatus, and wireless communication method
JP2007532642A (ja) *	2004-04-14	2007-11-15	セルジーン・コーポレーション	脊髄形成異常症候群の治療及び管理のための選択的サイトカイン阻害薬の使用法、及びそれを含む組成物
KR20070007945A (ko) *	2004-04-23	2007-01-16	셀진 코포레이션	폐 고혈압증의 치료 및 관리를 위한 ｐｄｅ4 조절인자의사용 방법 및 그를 포함하는 조성물
CN101052630A (zh)	2004-09-03	2007-10-10	细胞基因公司	取代的杂环化合物和其用途
US20070190070A1 (en) *	2004-09-03	2007-08-16	Zeldis Jerome B	Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
KR20070085454A (ko) *	2004-10-28	2007-08-27	셀진 코포레이션	중추신경계 손상의 치료 및 관리를 위하여 ｐｄｅ４조절제를 사용하는 방법 및 조성물
US20080138295A1 (en) *	2005-09-12	2008-06-12	Celgene Coporation	Bechet's disease using cyclopropyl-N-carboxamide
EA201171035A1 (ru)	2009-02-10	2012-02-28	Селджин Корпорейшн	Композиции, включающие модуляторы pde4, и способ их применения для лечения, профилактики и сопровождения туберкулеза
MX341050B (es)	2010-04-07	2016-08-05	Celgene Corp *	Metodos para tratar infeccion viral respiratoria.
EP2583098B1 (de)	2010-06-15	2018-08-08	Celgene Corporation	Biomarker zur behandlung von schuppenflechte
US8927725B2 (en)	2011-12-02	2015-01-06	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Thio compounds
WO2015175956A1 (en)	2014-05-16	2015-11-19	Celgene Corporation	Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators
US10682336B2 (en)	2015-10-21	2020-06-16	Amgen Inc.	PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS)

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3536809A (en)	1969-02-17	1970-10-27	Alza Corp	Medication method
US3598123A (en)	1969-04-01	1971-08-10	Alza Corp	Bandage for administering drugs
US3845770A (en)	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
US3916899A (en)	1973-04-25	1975-11-04	Alza Corp	Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en)	1976-02-02	1977-02-22	Alza Corporation	Osmotic system having laminar arrangement for programming delivery of active agent
US4215114A (en)	1976-11-12	1980-07-29	The Upjohn Company	Analgesic N-[2-(furyl-methylamino and 2-thienylmethylamino)cycloaliphatic]be
IE58110B1 (en)	1984-10-30	1993-07-14	Elan Corp Plc	Controlled release powder and process for its preparation
US5073543A (en)	1988-07-21	1991-12-17	G. D. Searle & Co.	Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it)	1989-03-22	1991-07-25	Bioresearch Spa	Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en)	1989-11-07	1992-06-09	Merck & Co., Inc.	Swelling modulated polymeric drug delivery device
KR0166088B1 (ko)	1990-01-23	1999-01-15	.	수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en)	1990-05-15	1998-03-31	Alkermes Controlled Therapeutics Inc. Ii	Controlled release of antiparasitic agents in animals
US5580578A (en)	1992-01-27	1996-12-03	Euro-Celtique, S.A.	Controlled release formulations coated with aqueous dispersions of acrylic polymers
JPH0625163A (ja) *	1992-07-03	1994-02-01	Ube Ind Ltd	Ｎ−（ジメトキシベンジル）フタルイミド類およびその製造法
AU5165093A (en) *	1992-10-08	1994-05-09	E.I. Du Pont De Nemours And Company	Fungicidal and miticidal aminopyrimidines
US5591767A (en)	1993-01-25	1997-01-07	Pharmetrix Corporation	Liquid reservoir transdermal patch for the administration of ketorolac
US5629327A (en)	1993-03-01	1997-05-13	Childrens Hospital Medical Center Corp.	Methods and compositions for inhibition of angiogenesis
US5541213A (en) *	1993-06-24	1996-07-30	Eisai Co., Ltd.	Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility
US5463063A (en)	1993-07-02	1995-10-31	Celgene Corporation	Ring closure of N-phthaloylglutamines
US5605914A (en) *	1993-07-02	1997-02-25	Celgene Corporation	Imides
US5698579A (en)	1993-07-02	1997-12-16	Celgene Corporation	Cyclic amides
CN1061036C (zh)	1993-11-30	2001-01-24	G·D·瑟尔公司	用于治疗炎症的取代的吡唑基苯磺酰胺类化合物
IT1270594B (it)	1994-07-07	1997-05-07	Recordati Chem Pharm	Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5703098A (en) *	1994-12-30	1997-12-30	Celgene Corporation	Immunotherapeutic imides/amides
US5801195A (en)	1994-12-30	1998-09-01	Celgene Corporation	Immunotherapeutic aryl amides
US5703092A (en)	1995-04-18	1997-12-30	The Dupont Merck Pharmaceutical Company	Hydroxamic acid compounds as metalloprotease and TNF inhibitors
US5728844A (en) *	1995-08-29	1998-03-17	Celgene Corporation	Immunotherapeutic agents
US5728845A (en)	1995-08-29	1998-03-17	Celgene Corporation	Immunotherapeutic nitriles
US5658940A (en)	1995-10-06	1997-08-19	Celgene Corporation	Succinimide and maleimide cytokine inhibitors
HU228769B1 (en)	1996-07-24	2013-05-28	Celgene Corp	Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US5635517B1 (en)	1996-07-24	1999-06-29	Celgene Corp	Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6281230B1 (en)	1996-07-24	2001-08-28	Celgene Corporation	Isoindolines, method of use, and pharmaceutical compositions
EP2070920B8 (de)	1996-07-24	2011-04-27	Celgene Corporation	Substituierte 2-(2,6-Dioxopiperidin-3-yl)-phthalimide und Oxoisoindoline und Verfahren zur Verringerung der TNF-Alpha-Stufen
US5798368A (en)	1996-08-22	1998-08-25	Celgene Corporation	Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
EP0918746B1 (de)	1996-08-12	2003-04-09	Celgene Corporation	Immunotherapeutische mittel und ihre anwendung in der reduzierung der cytokininwerte
HUP0003761A3 (en)	1997-07-31	2001-04-28	Celgene Corp Warren	Substituted alkanohydroxamic acids and pharmaceutical compositions containing them
US5874448A (en)	1997-11-18	1999-02-23	Celgene Corporation	Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
US5955476A (en)	1997-11-18	1999-09-21	Celgene Corporation	Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
SE9803710L (sv)	1998-09-25	2000-03-26	A & Science Invest Ab	Användning av vissa substanser för behandling av nervrotsskador
US6020358A (en)	1998-10-30	2000-02-01	Celgene Corporation	Substituted phenethylsulfones and method of reducing TNFα levels
DE60023123T2 (de)	1999-03-18	2006-06-22	Celgene Corp.	Substituierte 1-oxo- und 1,3-dioxoisoindoline und ihre verwendung in pharmazeutischen zusammensetzungen zur senkung des spiegels inflammatorisch wirkender cytokine
US6667316B1 (en)	1999-11-12	2003-12-23	Celgene Corporation	Pharmaceutically active isoindoline derivatives
US6699899B1 (en)	1999-12-21	2004-03-02	Celgene Corporation	Substituted acylhydroxamic acids and method of reducing TNFα levels
US6326388B1 (en)	1999-12-21	2001-12-04	Celgene Corporation	Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
US20030045552A1 (en)	2000-12-27	2003-03-06	Robarge Michael J.	Isoindole-imide compounds, compositions, and uses thereof

1994
- 1994-12-30 US US08/366,679 patent/US6429221B1/en not_active Expired - Fee Related
1995
- 1995-11-20 RU RU97112858/04A patent/RU2162078C2/ru not_active IP Right Cessation
- 1995-11-20 CZ CZ972036A patent/CZ203697A3/cs unknown
- 1995-11-20 AT AT95940847T patent/ATE337301T1/de not_active IP Right Cessation
- 1995-11-20 ES ES95940847T patent/ES2271948T3/es not_active Expired - Lifetime
- 1995-11-20 PT PT95940847T patent/PT800514E/pt unknown
- 1995-11-20 PL PL95321065A patent/PL185361B1/pl not_active IP Right Cessation
- 1995-11-20 NZ NZ297324A patent/NZ297324A/xx not_active IP Right Cessation
- 1995-11-20 KR KR1019970704510A patent/KR100466838B1/ko not_active IP Right Cessation
- 1995-11-20 JP JP52098696A patent/JP4118329B2/ja not_active Expired - Fee Related
- 1995-11-20 DK DK95940847T patent/DK0800514T3/da active
- 1995-11-20 KR KR10-2003-7016455A patent/KR20040007729A/ko not_active Application Discontinuation
- 1995-11-20 SK SK868-97A patent/SK86897A3/sk unknown
- 1995-11-20 WO PCT/US1995/015384 patent/WO1996020926A1/en active IP Right Grant
- 1995-11-20 HU HU9701849A patent/HUT77124A/hu unknown
- 1995-11-20 CA CA002208671A patent/CA2208671C/en not_active Expired - Fee Related
- 1995-11-20 DE DE69535195T patent/DE69535195T2/de not_active Expired - Lifetime
- 1995-11-20 AU AU42463/96A patent/AU709719B2/en not_active Ceased
- 1995-11-20 EP EP95940847A patent/EP0800514B1/de not_active Expired - Lifetime
1997
- 1997-06-23 FI FI972709A patent/FI972709A/fi unknown
1998
- 1998-02-17 HK HK98101231A patent/HK1004674A1/xx not_active IP Right Cessation
2002
- 2002-03-25 US US10/105,833 patent/US6844359B2/en not_active Expired - Fee Related
2004
- 2004-11-16 US US10/989,945 patent/US7329761B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
KR980700968A (ko)	1998-04-30
PL185361B1 (pl)	2003-04-30
PL321065A1 (en)	1997-11-24
PT800514E (pt)	2006-12-29
CA2208671A1 (en)	1996-07-11
CA2208671C (en)	2009-02-10
US6429221B1 (en)	2002-08-06
US6844359B2 (en)	2005-01-18
US20020143027A1 (en)	2002-10-03
EP0800514B1 (de)	2006-08-23
JP4118329B2 (ja)	2008-07-16
SK86897A3 (en)	1998-01-14
DK0800514T3 (da)	2006-12-27
ES2271948T3 (es)	2007-04-16
US7329761B2 (en)	2008-02-12
KR20040007729A (ko)	2004-01-24
KR100466838B1 (ko)	2005-09-02
ATE337301T1 (de)	2006-09-15
NZ297324A (en)	2000-03-27
RU2162078C2 (ru)	2001-01-20
AU4246396A (en)	1996-07-24
CZ203697A3 (en)	1997-11-12
HK1004674A1 (en)	1998-12-04
HUT77124A (hu)	1998-03-02
EP0800514A1 (de)	1997-10-15
DE69535195T2 (de)	2007-07-12
US20050090516A1 (en)	2005-04-28
FI972709A0 (fi)	1997-06-23
FI972709A (fi)	1997-08-29
WO1996020926A1 (en)	1996-07-11
JPH10511946A (ja)	1998-11-17
AU709719B2 (en)	1999-09-02

Legal Events

Date	Code	Title	Description
2007-09-13	8364	No opposition during term of opposition

Publication	Publication Date	Title
DE69535195D1 (de)	2006-10-05	Substituierte imide als tnf inhibitoren
PT862552E (pt)	2003-12-31	Succinimidas e maleimidas inibidoras de citocinas
DE69522961D1 (en)	2001-10-31	Immunotherapeutische arylamide
ATE259787T1 (de)	2004-03-15	Inhibitoren des tumor-necrosis-factors
EP1004572A3 (de)	2002-10-02	Aminen als Inhibitoren von TNF alpha
NO986103L (no)	1998-12-23	Substituerte indazol-derivater og deres anvendelse som fosfodiesterase (PDE)type IV - og tumornekrose-faktor (TNF)inhibitorer
NO991048D0 (no)	1999-03-03	Indazolderivater og deres anvendelse som inhibitorer av fosfodiesterase (PDE) type IV og fremstillingen av tumornekrosefaktor (TNF)
WO1998024763A3 (en)	1998-08-06	Immunotherapeutic imides/amides as pde iv and tnf inhibitors
EA199700186A1 (ru)	1998-02-26	Новые дипептидные амидины, используемые в качестве ингибиторов тромбина
ATE114467T1 (de)	1994-12-15	(+)-alpha-(2,3 dimethoxyphenyl)-1-(2- (fluorophenyl)ethyl>-4-piperidinmethanol.
DK0797437T3 (da)	2001-06-05	Immunterapeutiske imider/amider samt anvendelse deraf til at reducere niveauer af TNFalfa
GB8926611D0 (en)	1990-01-17	Compound and its use
DK1308444T3 (da)	2006-09-18	Substitueret 2(2,6 dioxo-3-fluorpiperidin-3-yl)-isoindoliner og deres anvendelse til reduktion af TNFalfa-niveau'er
ES2064229A1 (es)	1995-01-16	Nuevas 1,2-dihidro-2-oxopiridinas de formula i.